<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72248">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01985542</url>
  </required_header>
  <id_info>
    <org_study_id>The effects of immunotherapy</org_study_id>
    <nct_id>NCT01985542</nct_id>
  </id_info>
  <brief_title>The Effects of Immunotherapy in the Nose</brief_title>
  <acronym>Birch11</acronym>
  <official_title>The Molecular Biological Effects of Immunotherapy in the Nose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Institute of Occupational Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and
      other environmental insults. About 20 % of the European population suffers from pollen
      allergies. Birch pollen allergic rhinitis is the most common allergic disease in the
      Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of
      pollen allergies may be reduced by understanding the molecular biology of the nasal barriers
      during allergic response. Our aim is to observe the effect of season and birch pollen
      immunotherapy on the molecular biology of nasal epithelium and the microbiome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a controlled study with an intervention arm, and a control group of healthy
      volunteers. The population is composed of nonsmoking healthy adults and patients having
      birch or timothy pollen allergy with rhinoconjuctivitis symptoms and without other diseases.
      The diagnosis of pollen allergy is verified with positive history, skin prick test, and
      allergen specific IgE antibodies. Subjects undergo a spirometry with a bronchodilatator test
      and a histamine challenge. Quality of life and patient history data is collected by
      questionnaires. Four peripheral blood samples, as well as nasal cell swabs from nasal mucosa
      without local anesthesia are collected from each patient; in spring and winter before the
      group of the intervention arm starts with birch pollen subcutaneous immunotherapy; and
      during the first spring and winter when a subgroups has received the birch pollen
      immunotherapy. We plan to perform the following analyses for the nasal specimens:
      transcriptomics and their regulators, sequencing of 16SrRNA and RT-qPCR for assessing
      mucosal microbiome, mass spectrometry for analyses of proteins and protein-protein
      complexes, immunohistochemistry for tissue level localization and quantitation of proteins,
      in silico analyses for the data mining, integration and display. In addition we observe the
      alterations in inflammatory mediators after  in vitro allergen activation of purified
      peripheral blood leukocytes by ELISA and real time qPCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Changes in nasal epithelial transcriptomics after immunotherapy</measure>
    <time_frame>-6 months, 0 mo, 6 mo, 12 mo from the starting point of birch pollen SCIT</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in nasal epithelial transcriptomics after immunotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starts with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no immunotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>not starting with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>birch pollen subcutaneous immunotherapy</intervention_name>
    <description>birch pollen subcutaneous immunotherapy</description>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <other_name>birch pollen subcutaneous immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic rhinoconjunctivitis of birch pollen OR healthy controls

        Exclusion Criteria:

          -  smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring
             constant medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanna K Salmi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Mattila P, Renkonen J, Toppila-Salmi S, Parviainen V, Joenväärä S, Alff-Tuomala S, Nicorici D, Renkonen R. Time-series nasal epithelial transcriptomics during natural pollen exposure in healthy subjects and allergic patients. Allergy. 2010 Feb;65(2):175-83. doi: 10.1111/j.1398-9995.2009.02181.x. Epub 2009 Oct 5.</citation>
    <PMID>19804444</PMID>
  </reference>
  <reference>
    <citation>Joenväärä S, Mattila P, Renkonen J, Mäkitie A, Toppila-Salmi S, Lehtonen M, Salmi P, Lehti S, Mäkinen J, Sormunen R, Paavonen T, Renkonen R. Caveolar transport through nasal epithelium of birch pollen allergen Bet v 1 in allergic patients. J Allergy Clin Immunol. 2009 Jul;124(1):135-142.e1-21. doi: 10.1016/j.jaci.2008.11.048. Epub 2009 Apr 2.</citation>
    <PMID>19344938</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Sanna Salmi</investigator_full_name>
    <investigator_title>MD PhD, Docent</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
